Published in Proc Natl Acad Sci U S A on July 05, 2005
A previously unknown reovirus of bat origin is associated with an acute respiratory disease in humans. Proc Natl Acad Sci U S A (2007) 2.88
Tumor cell marker PVRL4 (nectin 4) is an epithelial cell receptor for measles virus. PLoS Pathog (2011) 2.74
Two key residues in ephrinB3 are critical for its use as an alternative receptor for Nipah virus. PLoS Pathog (2006) 2.26
A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute nipah virus infection. PLoS Pathog (2009) 2.09
Host cell recognition by the henipaviruses: crystal structures of the Nipah G attachment glycoprotein and its complex with ephrin-B3. Proc Natl Acad Sci U S A (2008) 2.08
Refolding of a paramyxovirus F protein from prefusion to postfusion conformations observed by liposome binding and electron microscopy. Proc Natl Acad Sci U S A (2006) 2.03
Potent neutralization of Hendra and Nipah viruses by human monoclonal antibodies. J Virol (2006) 2.00
N-glycans on Nipah virus fusion protein protect against neutralization but reduce membrane fusion and viral entry. J Virol (2006) 1.97
Feline model of acute nipah virus infection and protection with a soluble glycoprotein-based subunit vaccine. J Virol (2006) 1.87
Viral entry mechanisms: the increasing diversity of paramyxovirus entry. FEBS J (2009) 1.82
Functional interaction between paramyxovirus fusion and attachment proteins. J Biol Chem (2008) 1.78
Cedar virus: a novel Henipavirus isolated from Australian bats. PLoS Pathog (2012) 1.68
Identification of Hendra virus G glycoprotein residues that are critical for receptor binding. J Virol (2007) 1.61
Development of an acute and highly pathogenic nonhuman primate model of Nipah virus infection. PLoS One (2010) 1.54
Mutation of YMYL in the Nipah virus matrix protein abrogates budding and alters subcellular localization. J Virol (2006) 1.52
Paramyxovirus fusion and entry: multiple paths to a common end. Viruses (2012) 1.49
Polybasic KKR motif in the cytoplasmic tail of Nipah virus fusion protein modulates membrane fusion by inside-out signaling. J Virol (2007) 1.48
A novel receptor-induced activation site in the Nipah virus attachment glycoprotein (G) involved in triggering the fusion glycoprotein (F). J Biol Chem (2008) 1.44
Single amino acid changes in the Nipah and Hendra virus attachment glycoproteins distinguish ephrinB2 from ephrinB3 usage. J Virol (2007) 1.44
Modes of paramyxovirus fusion: a Henipavirus perspective. Trends Microbiol (2011) 1.42
Residues in the stalk domain of the hendra virus g glycoprotein modulate conformational changes associated with receptor binding. J Virol (2008) 1.40
A recombinant Hendra virus G glycoprotein-based subunit vaccine protects ferrets from lethal Hendra virus challenge. Vaccine (2011) 1.39
Kaposi's sarcoma-associated herpesvirus interacts with EphrinA2 receptor to amplify signaling essential for productive infection. Proc Natl Acad Sci U S A (2012) 1.38
Glycoprotein interactions in paramyxovirus fusion. Future Virol (2009) 1.36
A neutralizing human monoclonal antibody protects african green monkeys from hendra virus challenge. Sci Transl Med (2011) 1.35
Paramyxoviruses: different receptors - different mechanisms of fusion. Trends Microbiol (2008) 1.34
Structural and mechanistic studies of measles virus illuminate paramyxovirus entry. PLoS Pathog (2011) 1.34
Structural rearrangements of the central region of the morbillivirus attachment protein stalk domain trigger F protein refolding for membrane fusion. J Biol Chem (2012) 1.33
Crystal structure and carbohydrate analysis of Nipah virus attachment glycoprotein: a template for antiviral and vaccine design. J Virol (2008) 1.32
Quantitative analysis of Nipah virus proteins released as virus-like particles reveals central role for the matrix protein. Virol J (2007) 1.30
Productive hepatitis C virus infection of stem cell-derived hepatocytes reveals a critical transition to viral permissiveness during differentiation. PLoS Pathog (2012) 1.29
Inhibition of Henipavirus fusion and infection by heptad-derived peptides of the Nipah virus fusion glycoprotein. Virol J (2005) 1.21
Establishment of a Nipah virus rescue system. Proc Natl Acad Sci U S A (2006) 1.20
Inhibition of hendra virus fusion. J Virol (2006) 1.18
Integrin alphavbeta1 promotes infection by human metapneumovirus. Proc Natl Acad Sci U S A (2009) 1.13
Mechanism for active membrane fusion triggering by morbillivirus attachment protein. J Virol (2012) 1.09
Cysteines in the stalk of the nipah virus G glycoprotein are located in a distinct subdomain critical for fusion activation. J Virol (2012) 1.08
Human metapneumovirus (HMPV) binding and infection are mediated by interactions between the HMPV fusion protein and heparan sulfate. J Virol (2012) 1.08
Unraveling a three-step spatiotemporal mechanism of triggering of receptor-induced Nipah virus fusion and cell entry. PLoS Pathog (2013) 1.08
Measles virus hemagglutinin: structural insights into cell entry and measles vaccine. Front Microbiol (2011) 1.06
Nipah virus uses leukocytes for efficient dissemination within a host. J Virol (2011) 1.05
A new model for Hendra virus encephalitis in the mouse. PLoS One (2012) 1.04
Triggering of the newcastle disease virus fusion protein by a chimeric attachment protein that binds to Nipah virus receptors. J Biol Chem (2011) 1.03
Envelope protein dynamics in paramyxovirus entry. MBio (2013) 1.03
Entry and fusion of emerging paramyxoviruses. PLoS Pathog (2010) 1.02
A quantitative and kinetic fusion protein-triggering assay can discern distinct steps in the nipah virus membrane fusion cascade. J Virol (2010) 1.01
Activation of the Nipah virus fusion protein in MDCK cells is mediated by cathepsin B within the endosome-recycling compartment. J Virol (2012) 1.00
Henipavirus outbreaks to antivirals: the current status of potential therapeutics. Curr Opin Virol (2012) 0.98
Potent human monoclonal antibodies against SARS CoV, Nipah and Hendra viruses. Expert Opin Biol Ther (2009) 0.98
Vaccine potential of Nipah virus-like particles. PLoS One (2011) 0.97
Biochemical, conformational, and immunogenic analysis of soluble trimeric forms of henipavirus fusion glycoproteins. J Virol (2012) 0.96
Tyrosine residues in the cytoplasmic domains affect sorting and fusion activity of the Nipah virus glycoproteins in polarized epithelial cells. J Virol (2010) 0.95
Lethal Nipah virus infection induces rapid overexpression of CXCL10. PLoS One (2012) 0.95
Pathology of acute henipavirus infection in humans and animals. Patholog Res Int (2011) 0.95
Timing is everything: Fine-tuned molecular machines orchestrate paramyxovirus entry. Virology (2015) 0.94
Differential rates of protein folding and cellular trafficking for the Hendra virus F and G proteins: implications for F-G complex formation. J Virol (2009) 0.93
Targeted strategies for henipavirus therapeutics. Open Virol J (2007) 0.93
Henipavirus receptor usage and tropism. Curr Top Microbiol Immunol (2012) 0.91
Cells under siege: viral glycoprotein interactions at the cell surface. J Struct Biol (2011) 0.91
Shared paramyxoviral glycoprotein architecture is adapted for diverse attachment strategies. Biochem Soc Trans (2010) 0.91
Emerging paramyxoviruses: molecular mechanisms and antiviral strategies. Expert Rev Mol Med (2011) 0.90
Structural basis of efficient contagion: measles variations on a theme by parainfluenza viruses. Curr Opin Virol (2014) 0.90
Nipah virus entry and egress from polarized epithelial cells. J Virol (2013) 0.89
Nipah virus infection and glycoprotein targeting in endothelial cells. Virol J (2010) 0.89
Surface density of the Hendra G protein modulates Hendra F protein-promoted membrane fusion: role for Hendra G protein trafficking and degradation. Virology (2007) 0.89
Selective receptor expression restricts Nipah virus infection of endothelial cells. Virol J (2008) 0.89
Detection of receptor-induced glycoprotein conformational changes on enveloped virions by using confocal micro-Raman spectroscopy. J Virol (2013) 0.89
New insights into the Hendra virus attachment and entry process from structures of the virus G glycoprotein and its complex with Ephrin-B2. PLoS One (2012) 0.89
Unity in diversity: shared mechanism of entry among paramyxoviruses. Prog Mol Biol Transl Sci (2014) 0.88
Endothelial galectin-1 binds to specific glycans on nipah virus fusion protein and inhibits maturation, mobility, and function to block syncytia formation. PLoS Pathog (2010) 0.88
Surface glycoproteins of an African henipavirus induce syncytium formation in a cell line derived from an African fruit bat, Hypsignathus monstrosus. J Virol (2013) 0.88
Identification of a region in the stalk domain of the nipah virus receptor binding protein that is critical for fusion activation. J Virol (2013) 0.88
Site occupancy and glycan compositional analysis of two soluble recombinant forms of the attachment glycoprotein of Hendra virus. Glycobiology (2011) 0.88
Probing the paramyxovirus fusion (F) protein-refolding event from pre- to postfusion by oxidative footprinting. Proc Natl Acad Sci U S A (2014) 0.87
Henipavirus mediated membrane fusion, virus entry and targeted therapeutics. Viruses (2012) 0.87
Vaccination of ferrets with a recombinant G glycoprotein subunit vaccine provides protection against Nipah virus disease for over 12 months. Virol J (2013) 0.86
A functional henipavirus envelope glycoprotein pseudotyped lentivirus assay system. Virol J (2010) 0.86
C-terminal tyrosine residues modulate the fusion activity of the Hendra virus fusion protein. Biochemistry (2011) 0.86
Co-assembly of viral envelope glycoproteins regulates their polarized sorting in neurons. PLoS Pathog (2014) 0.85
Individual N-glycans added at intervals along the stalk of the Nipah virus G protein prevent fusion but do not block the interaction with the homologous F protein. J Virol (2013) 0.85
Nipah virion entry kinetics, composition, and conformational changes determined by enzymatic virus-like particles and new flow virometry tools. J Virol (2014) 0.85
Molecular recognition of human ephrinB2 cell surface receptor by an emergent African henipavirus. Proc Natl Acad Sci U S A (2015) 0.84
Residues in the hendra virus fusion protein transmembrane domain are critical for endocytic recycling. J Virol (2012) 0.84
Hendra and nipah infection: pathology, models and potential therapies. Infect Disord Drug Targets (2011) 0.84
Nipah virus envelope-pseudotyped lentiviruses efficiently target ephrinB2-positive stem cell populations in vitro and bypass the liver sink when administered in vivo. J Virol (2012) 0.83
Hendra Virus Infection in Dog, Australia, 2013. Emerg Infect Dis (2015) 0.83
Crystal Structure of the Pre-fusion Nipah Virus Fusion Glycoprotein Reveals a Novel Hexamer-of-Trimers Assembly. PLoS Pathog (2015) 0.83
Ephrin-B2 expression critically influences Nipah virus infection independent of its cytoplasmic tail. Virol J (2008) 0.83
Immunization strategies against henipaviruses. Curr Top Microbiol Immunol (2012) 0.83
Interactions of human complement with virus particles containing the Nipah virus glycoproteins. J Virol (2011) 0.82
Ephrin-B2 and ephrin-B3 as functional henipavirus receptors. Semin Cell Dev Biol (2011) 0.81
Induction of neutralizing antibodies to Hendra and Nipah glycoproteins using a Venezuelan equine encephalitis virus in vivo expression system. Vaccine (2010) 0.81
A recombinant Hendra virus G glycoprotein subunit vaccine protects nonhuman primates against Hendra virus challenge. J Virol (2014) 0.81
Subclinical infection without encephalitis in mice following intranasal exposure to Nipah virus-Malaysia and Nipah virus-Bangladesh. Virol J (2014) 0.81
PCalign: a method to quantify physicochemical similarity of protein-protein interfaces. BMC Bioinformatics (2015) 0.80
Attachment protein G of an African bat henipavirus is differentially restricted in chiropteran and nonchiropteran cells. J Virol (2014) 0.79
Infection of primary neurons mediated by nipah virus envelope proteins: role of host target cells in antiviral action. J Virol (2011) 0.79
Serological evidence of henipavirus exposure in cattle, goats and pigs in Bangladesh. PLoS Negl Trop Dis (2014) 0.79
HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science (1996) 26.19
Mechanisms of viral membrane fusion and its inhibition. Annu Rev Biochem (2001) 8.96
The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell (1993) 7.71
A morbillivirus that caused fatal disease in horses and humans. Science (1995) 7.61
Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus. J Virol (1993) 7.27
SLAM (CDw150) is a cellular receptor for measles virus. Nature (2000) 6.07
Paramyxovirus fusion: a hypothesis for changes. Virology (1993) 4.98
Fusogenic mechanisms of enveloped-virus glycoproteins analyzed by a novel recombinant vaccinia virus-based assay quantitating cell fusion-dependent reporter gene activation. J Virol (1994) 4.65
Structural basis for paramyxovirus-mediated membrane fusion. Mol Cell (1999) 4.17
Crystal structure of the multifunctional paramyxovirus hemagglutinin-neuraminidase. Nat Struct Biol (2000) 4.10
The natural history of Hendra and Nipah viruses. Microbes Infect (2001) 3.77
Membrane fusion machines of paramyxoviruses: capture of intermediates of fusion. EMBO J (2001) 3.76
Regulated expression of foreign genes in vaccinia virus under the control of bacteriophage T7 RNA polymerase and the Escherichia coli lac repressor. J Virol (1992) 3.53
Structural basis for membrane fusion by enveloped viruses. Mol Membr Biol (1999) 3.26
Diverse roles of eph receptors and ephrins in the regulation of cell migration and tissue assembly. Dev Cell (2004) 3.11
Nipah virus outbreak in Malaysia. J Clin Virol (2003) 3.00
Transmission studies of Hendra virus (equine morbillivirus) in fruit bats, horses and cats. Aust Vet J (1998) 2.91
Virus entry, assembly, budding, and membrane rafts. Microbiol Mol Biol Rev (2003) 2.68
Molecular characterization of Nipah virus, a newly emergent paramyxovirus. Virology (2000) 2.63
Protein-protein interactions within paramyxoviruses identified by native disulfide bonding or reversible chemical cross-linking. J Virol (1980) 2.40
Structure of the haemagglutinin-neuraminidase from human parainfluenza virus type III. J Mol Biol (2004) 2.33
Morbilliviruses use signaling lymphocyte activation molecules (CD150) as cellular receptors. J Virol (2001) 2.29
Differential gene expression of Eph receptors and ephrins in benign human tissues and cancers. Clin Chem (2004) 2.17
A golden hamster model for human acute Nipah virus infection. Am J Pathol (2003) 2.15
Experimental Nipah virus infection in pigs and cats. J Comp Pathol (2002) 2.03
Receptor binding, fusion inhibition, and induction of cross-reactive neutralizing antibodies by a soluble G glycoprotein of Hendra virus. J Virol (2005) 1.89
Treatment of acute Nipah encephalitis with ribavirin. Ann Neurol (2001) 1.87
Nipah virus outbreak(s) in Bangladesh, January-April 2004. Wkly Epidemiol Rec (2004) 1.81
Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody. J Virol (2004) 1.80
Membrane fusion tropism and heterotypic functional activities of the Nipah virus and Hendra virus envelope glycoproteins. J Virol (2002) 1.69
Sequence and structure alignment of Paramyxoviridae attachment proteins and discovery of enzymatic activity for a morbillivirus hemagglutinin. J Virol (1997) 1.67
Studies with cross-linking reagents on the oligomeric form of the paramyxovirus fusion protein. Virology (1994) 1.63
Structure, function, and intracellular processing of paramyxovirus membrane proteins. Virus Res (1988) 1.54
The complete genome sequence of J virus reveals a unique genome structure in the family Paramyxoviridae. J Virol (2005) 1.47
Functional expression and membrane fusion tropism of the envelope glycoproteins of Hendra virus. Virology (2001) 1.47
Eph-ephrin promiscuity is now crystal clear. Nat Neurosci (2004) 1.44
Characterization of a region of the measles virus hemagglutinin sufficient for its dimerization. J Virol (2000) 1.38
Crystal structure of an ephrin ectodomain. Dev Cell (2001) 1.37
Modulation of entry of enveloped viruses by cholesterol and sphingolipids (Review). Mol Membr Biol (2003) 1.30
Reducing agent-sensitive dimerization of the hemagglutinin-neuraminidase glycoprotein of Newcastle disease virus correlates with the presence of cysteine at residue 123. Virology (1987) 1.30
Functional and structural interactions between measles virus hemagglutinin and CD46. J Virol (1995) 1.29
Susceptibility of cats to equine morbillivirus. Aust Vet J (1996) 1.29
Cell biology of virus entry. Cell (2000) 1.29
Eph receptors, ephrins, and synaptic function. Neuroscientist (2004) 1.29
Fatal fruit bat virus sparks epidemics in southern Asia. Nature (2004) 1.26
A novel P/V/C gene in a new member of the Paramyxoviridae family, which causes lethal infection in humans, horses, and other animals. J Virol (1998) 1.25
The attachment protein of Hendra virus has high structural similarity but limited primary sequence homology compared with viruses in the genus Paramyxovirus. Virology (1998) 1.22
Introduction to Current focus on Hendra and Nipah viruses. Microbes Infect (2001) 1.20
The cleavage activation and sites of glycosylation in the fusion protein of Hendra virus. Virus Res (2000) 1.18
Emerging infectious diseases. Nipah virus (or a cousin) strikes again. Science (2004) 1.13
Nipah encephalitis outbreak in Malaysia. Ann Acad Med Singapore (2003) 1.08
The lesions of experimental equine morbillivirus disease in cats and guinea pigs. Vet Pathol (1997) 1.06
Viral glycoprotein-mediated cell fusion assays using vaccinia virus vectors. Methods Mol Biol (2004) 0.99
The role of lipid microdomains in virus biology. Subcell Biochem (2004) 0.98
Henipaviruses: recent observations on regulation of transcription and the nature of the cell receptor. Arch Virol Suppl (2004) 0.86
Cell biology of virus entry: a review of selected topics from the 3rd International Frederick meeting. Biochim Biophys Acta (2003) 0.80
Bats are natural reservoirs of SARS-like coronaviruses. Science (2005) 13.44
Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature (2007) 11.73
Evaluation of gene expression measurements from commercial microarray platforms. Nucleic Acids Res (2003) 8.08
Structure of a V3-containing HIV-1 gp120 core. Science (2005) 7.69
Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120. Proc Natl Acad Sci U S A (2004) 5.15
Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J Virol (2003) 4.49
Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science (2009) 4.20
Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens. Biochem Biophys Res Commun (2009) 3.38
Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature (2013) 3.27
Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature (2013) 3.14
Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes. Proc Natl Acad Sci U S A (2002) 3.08
Hendra and Nipah viruses: different and dangerous. Nat Rev Microbiol (2006) 2.95
A previously unknown reovirus of bat origin is associated with an acute respiratory disease in humans. Proc Natl Acad Sci U S A (2007) 2.88
Improved rapid amplification of cDNA ends (RACE) for mapping both the 5' and 3' terminal sequences of paramyxovirus genomes. J Virol Methods (2005) 2.66
Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood (2012) 2.52
Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination. Virology (2008) 2.37
Comparative analysis of bat genomes provides insight into the evolution of flight and immunity. Science (2012) 2.29
Antibodies to SARS coronavirus in civets. Emerg Infect Dis (2004) 2.27
The SARS-CoV S glycoprotein: expression and functional characterization. Biochem Biophys Res Commun (2003) 2.23
A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute nipah virus infection. PLoS Pathog (2009) 2.09
Host cell recognition by the henipaviruses: crystal structures of the Nipah G attachment glycoprotein and its complex with ephrin-B3. Proc Natl Acad Sci U S A (2008) 2.08
Crystal structure of the broadly cross-reactive HIV-1-neutralizing Fab X5 and fine mapping of its epitope. Biochemistry (2004) 2.01
Thiol/disulfide exchange is a prerequisite for CXCR4-tropic HIV-1 envelope-mediated T-cell fusion during viral entry. Blood (2003) 2.00
Potent neutralization of Hendra and Nipah viruses by human monoclonal antibodies. J Virol (2006) 2.00
Neutralization assays for differential henipavirus serology using Bio-Plex protein array systems. J Virol Methods (2007) 1.99
Long-term survival of an urban fruit bat seropositive for Ebola and Lagos bat viruses. PLoS One (2010) 1.95
Bats and their virome: an important source of emerging viruses capable of infecting humans. Curr Opin Virol (2012) 1.91
Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody. J Biol Chem (2006) 1.90
Receptor binding, fusion inhibition, and induction of cross-reactive neutralizing antibodies by a soluble G glycoprotein of Hendra virus. J Virol (2005) 1.89
Broadly cross-reactive HIV neutralizing human monoclonal antibody Fab selected by sequential antigen panning of a phage display library. J Immunol Methods (2003) 1.87
Feline model of acute nipah virus infection and protection with a soluble glycoprotein-based subunit vaccine. J Virol (2006) 1.87
Induction of prolonged survival of CD4+ T lymphocytes by intermittent IL-2 therapy in HIV-infected patients. J Clin Invest (2005) 1.82
Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody. J Virol (2004) 1.80
Dissection of human immunodeficiency virus type 1 entry with neutralizing antibodies to gp41 fusion intermediates. J Virol (2002) 1.79
Regulation of human immunodeficiency virus type 1 envelope glycoprotein fusion by a membrane-interactive domain in the gp41 cytoplasmic tail. J Virol (2005) 1.76
Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proc Natl Acad Sci U S A (2007) 1.76
Filamin-A regulates actin-dependent clustering of HIV receptors. Nat Cell Biol (2007) 1.71
Membrane fusion tropism and heterotypic functional activities of the Nipah virus and Hendra virus envelope glycoproteins. J Virol (2002) 1.69
Cedar virus: a novel Henipavirus isolated from Australian bats. PLoS Pathog (2012) 1.68
Vertical transmission and fetal replication of Nipah virus in an experimentally infected cat. J Infect Dis (2007) 1.68
Ebola virus antibodies in fruit bats, Ghana, West Africa. Emerg Infect Dis (2012) 1.62
Identification of Hendra virus G glycoprotein residues that are critical for receptor binding. J Virol (2007) 1.61
Improved breadth and potency of an HIV-1-neutralizing human single-chain antibody by random mutagenesis and sequential antigen panning. J Mol Biol (2004) 1.61
Hendra virus V protein inhibits interferon signaling by preventing STAT1 and STAT2 nuclear accumulation. J Virol (2003) 1.59
Ebola Reston virus infection of pigs: clinical significance and transmission potential. J Infect Dis (2011) 1.58
Increased efficacy of HIV-1 neutralization by antibodies at low CCR5 surface concentration. Biochem Biophys Res Commun (2006) 1.58
Development of an acute and highly pathogenic nonhuman primate model of Nipah virus infection. PLoS One (2010) 1.54
Inhibitors of protein-disulfide isomerase prevent cleavage of disulfide bonds in receptor-bound glycoprotein 120 and prevent HIV-1 entry. J Biol Chem (2002) 1.54